首页> 外文期刊>Expert opinion on biological therapy >Immunological and hematological toxicities challenging clinical translation of nucleic acid-based therapeutics
【24h】

Immunological and hematological toxicities challenging clinical translation of nucleic acid-based therapeutics

机译:免疫学和血液学毒性挑战基于核酸的疗法的临床翻译

获取原文
获取原文并翻译 | 示例
           

摘要

Introduction: Nucleic acid-based therapeutics (NATs) are proven agents in correcting disorders caused by gene mutations, as treatments against cancer, microbes and viruses, and as vaccine adjuvants. Although many traditional small molecule NATs have been approved for clinical use, commercialization of macromolecular NATs has been considerably slower, and only a few have successfully reached the market. Preclinical and clinical evaluation of macromolecular NATs has revealed many assorted challenges in immunotoxicity, hematotoxicity, pharmacokinetics (PKs), toxicology and formulation. Extensive review has been given to the PK and toxicological concerns of NATs including approaches designed to overcome these issues. Immunological and hematological issues are a commonly reported side effect of NAT treatment; however, literature exploring the mechanistic background of these effects is sparse.
机译:简介:核酸治疗剂(NATs)已被证明可纠正因基因突变引起的疾病,作为抗癌,微生物和病毒的治疗方法以及疫苗佐剂。尽管许多传统的小分子NAT已被批准用于临床,但大分子NAT的商业化进程相当缓慢,只有少数成功地进入了市场。大分子NAT的临床前和临床评估表明,免疫毒性,血液毒性,药代动力学(PKs),毒理学和制剂方面存在许多挑战。已经对NAT的PK和毒理学问题进行了广泛的审查,包括旨在克服这些问题的方法。免疫学和血液学问题是NAT治疗常见的副作用。然而,探索这些作用机理的文献很少。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号